NEW YORK, July 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
iPS cell Generation" Patent Landscape 2011
http://www.reportlinker.com/p0570294/iPS-cell-Generation"-Patent-Landscape-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy
IP Overview presents a patent mapping analysis of the "induced pluripotent stem cell" field.
Stem cell based therapies raise high hope concerning the treatment of several human diseases. However, there still exists a great deal of social, economic and scientific uncertainty surrounding the use of stem cells, especially over the use of human embryonic stem cells. The recent development of induced pluripotent stem cells (iPS) bypass some of those critical issues by developing pluripotent stem cells customized to the patient, easy to produce and that does not require the use of embryos.
Several techniques have been developed and protected for the production of iPS cells such as the Thomson's and Yamanaka's techniques that have been published simultaneously. Indeed, since 2005, many new players (mainly institutional applicants) positioned on the thematic to bring their own brick to this technology. The setting up of winning patent strategies by existing actors and potential new entrants requires the ability to navigate accurately through the current patent landscape.
This patent landscape analysis on the field of "iPS cell generation" shows a boom of patent filings in this sector since 2007. Due to the youth of the technology, a majority of patent applications have been filed by institutional applicants such as the institutes of the historical inventors Shinya Yamanaka (Kyoto University - 25 filings), James Thomson (University of Wisconsin-Madison - 2 filings) or Rudolf Jaenisch (Whitehead Biomedical Institute – 7 filings). However several young companies have positioned themselves early on the thematic and have tried to set up interesting deals with well positioned institutional applicants such as iPierian that obtained non-exclusive worldwide rights from Kyoto University.
In this promising sector driven by potential important markets and where 244 patent families have been filed, this report "IP Overview – iPS Cell Generation – 2011" provides you with a comprehensive panorama of the intellectual property landscape and helps you:
- Position your company's R&D and IP Portfolio
- Identify key inventors and key players involved in the generation of iPS cells
- Understand the collaboration networks and their dynamics
- Discover new trends and emerging topics
Please note that a three months access to the full patent database is also included
Table of contents
Brief outline of the technology: dedifferentiation methodologies
Generalities
Brief outline of the technology: reprogramming techniques
Patent query
Evolution of patent filings (1995-2010)
Evolution of the number of applicants
Industrial & institutional filings over time
Map of extensions
Map and evolution of priority filings
Evolution and location of patent filings
Main applicants on the entire period (1995-2010)
Part of the portfolio hold by the first 10 applicants
Breakdown of filings of the main industrial/institutional applicants over time
Main co-filings between applicants
Applicants and their affiliates
Analysis of patent applicants
Analysis of inventors
List of the main inventors
Main research teams
Topics of patent filings
Breakdown of the portfolio (for each breakdown are presented the evolution of filings
and the positioning of institutional applicants, industrial applicants and inventors)
Breakdown of the portfolio
1/iPSc generation techniques
Citation & Extension Analysis
List of the most cited patents and patent applications
List of the most extended patents & patent applications
Granting & Re-examination
List of granted patents
Re-examination
Conclusion -Appendices
Conclusive comments
Appendix –Applicant focuses
To order this report:
Biological Therapy Industry: iPS cell Generation" Patent Landscape 2011
Biological Therapy Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article